RTC
NVCR icon

Riverview Trust Company’s NovoCure NVCR Stock Holding History

Riverview Trust Company’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-181
Closed -$15K – 817
2022
Q1 		$15K Buy
+181
New +$13.3K 0.01% 617

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Riverview Trust Company's NVCR Position: Q2 2022 in Review

Riverview Trust Company sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 181 shares — an estimated $15K sold.

Riverview Trust Company first reported a position in NVCR in Q1 2022 and held it in 1 quarter. The position peaked at $15K in Q1 2022. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

  • Riverview Trust Company reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
  • Riverview Trust Company sold 181 NovoCure shares in Q2 2022, an estimated $15K.
  • Riverview Trust Company first reported a position in NovoCure in Q1 2022 and held it in 1 quarter.
  • Riverview Trust Company's NovoCure position peaked at $15K in Q1 2022.
  • 316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Riverview Trust Company's 13F filing for Q2 2022, filed 27 Jul 2022.